In May 2019, ACCC and SITC hosted a by-invitation Joint Immuno-Oncology Policy Summit in Washington, D.C. The interdisciplinary discussion focused on next steps in advancing immunotherapy for cancer with a focus on three areas: telehealth, CAR T implications, and care coordination and workforce issues. In this video, summit participants Sarah Murawski, MPAS, PA-C, Hematology/Oncology, Stem Cell Transplant, Cellular Therapy Nocturnist, Vanderbilt Ingram Cancer Center, and Robert Richards, MBA, Administrative Director, Cell Therapy and Transplant, Penn Medicine, UPenn Health System, talk about the future of CAR-T therapy, the need for adequate reimbursement for CAR T, and the potential role telehealth may play in expanding access to this promising new therapy.
Learn about dermatology’s role in the cancer care continuum and how cancer teams can better integrate dermatology into the immunotherapy care process.
We explore how immunotherapy clinical trials have been affected by the pandemic and what cancer programs can do to safely and effectively administer clinical trials.
Download a summary of what occured during the ACCC 45th Annual Meeting & Cancer Center Business Summit in March 2019, where a Deep Dive Workshop on Real-World Integration of Immuno-Oncology brought together an expert panel for a focused discussion on step therapy in the context of immunotherapeutics. Panelists explored step therapy from the perspective of different members of the care team, including a patient advocate.